AcquisitionsMay 7, 2026, 07:38 AM
Collegium to Acquire AZSTARYS for $650M; Q1 Net Income Up 499%
AI Summary
Collegium Pharmaceutical announced an agreement to acquire AZSTARYS, an ADHD treatment, for $650 million in cash plus up to $135 million in milestone payments, expected to close in Q2 2026. Concurrently, the company reported strong first-quarter 2026 financial results, with net income surging 499% to $14.5 million and diluted earnings per share increasing to $0.40. Net product revenues grew 8.9% year-over-year to $193.5 million.
Key Highlights
- Collegium to acquire AZSTARYS for $650M cash, plus up to $135M milestones.
- Q1 2026 net income increased 499% to $14.5M from $2.4M YoY.
- Diluted EPS rose to $0.40 in Q1 2026, up from $0.07 in Q1 2025.
- Product revenues, net, grew 8.9% to $193.5M in Q1 2026.
- Belbuca product revenue was $52.6M in Q1 2026.
- Xtampza ER product revenue was $50.8M in Q1 2026.
- Jornay PM product revenue was $38.9M in Q1 2026.
- Net cash provided by operating activities was $57.1M in Q1 2026.